Efficacy of Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes Mellitus
- 12 July 2004
- journal article
- review article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 164 (13) , 1395-1404
- https://doi.org/10.1001/archinte.164.13.1395
Abstract
Background Obesity is closely related to type 2 diabetes mellitus, and weight reduction is an important part of the care delivered to obese persons with diabetes. The objective of this review was to assess the efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes. Methods A systematic review of the literature was performed, and studies were included if pharmacotherapy was used as the primary strategy for weight loss among adults with type 2 diabetes. Published and unpublished studies with any design were included. A random effects model was used to combine outcomes from randomized controlled trials. Results Sufficient data for the meta-analysis were available for fluoxetine, orlistat, and sibutramine. Fourteen randomized, placebo-controlled trials were included in the review, with a total of 2231 patients. Pharmacotherapy produced modest reductions in weight for fluoxetine (3.4 kg [95% confidence interval (CI), 1.7-5.2 kg] at 8-16 weeks of follow-up; 5.1 kg [95% CI, 3.3-6.9 kg] at 24-30 weeks; and 5.8 kg [ 95% CI, 0.8-10.8 kg] at 52 weeks); orlistat (2.6 kg [95% CI, 2.1-3.2 kg] [2.6% loss] at 52 weeks); and sibutramine (4.5 kg [95% CI, 1.8-7.2 kg] [3.3% loss] at up to 26 weeks). Glycated hemoglobin was also modestly reduced: fluoxetine (1.0% [95% CI, 0.4%-1.5%] at 8-16 weeks; 1.0% [95% 0.6%-1.4%] at 24-30 weeks; and 1.8% [95% CI, –0.2%-3.8%] at 52 weeks); orlistat (0.4% [95% CI, 0.3%-0.5%]); and sibutramine (0.7% [95% CI, –0.5%-1.9%]). Gastrointestinal adverse effects were common with orlistat; tremor, somnolence, and sweating with fluoxetine; and palpitations with sibutramine. Conclusions Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 26 to 52 weeks. However, the magnitude of weight loss was modest, and the long-term health benefits and safety remain unclear. Interventions that combine pharmacologic therapy with intensive behavioral interventions may be more effective but need additional research.This publication has 38 references indexed in Scilit:
- Prevalence and Trends in Obesity Among US Adults, 1999-2000JAMA, 2002
- The Continuing Epidemics of Obesity and Diabetes in the United StatesJAMA, 2001
- Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose ToleranceNew England Journal of Medicine, 2001
- Weight loss and mortality in type 2 diabetes.Diabetes Care, 2000
- Intentional weight loss and mortality among overweight individuals with diabetes.Diabetes Care, 2000
- Diabetes trends in the U.S.: 1990-1998.Diabetes Care, 2000
- The Spread of the Obesity Epidemic in the United States, 1991-1998JAMA, 1999
- The Prevention and Treatment of Obesity: Application to type 2 diabetesDiabetes Care, 1997
- Review: The treatment and prevention of obesity: a systematic review of the literatureInternational Journal of Obesity, 1997
- Strategies for Improving Maintenance of Weight Loss: Toward a continuous care model of obesity managementDiabetes Care, 1993